Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

Published byAgnese Carbone Modified over 6 years ago

Similar presentations

Presentation on theme: "A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,"— Presentation transcript:

1 A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu, MD, FRCPC, Baktiar Hasan, PhD, Lesley Seymour, MD, Keyue Ding, PhD, Frances A. Shepherd, MD, FRCPC  Journal of Thoracic Oncology  Volume 3, Issue 6, Pages (June 2008) DOI: /JTO.0b013e Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Overall survival by prognostic subgroup for erlotinib and placebo patients. (A) Erlotinib, and (B) Placebo. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e ) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A comparison of survival by treatment group for the four prognostic subgroups identified by the prognostic index model. (A) Low Risk, (B) Intermediate Low Risk, (C) Intermediate High Risk, and (D) High Risk. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e ) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,"

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
Pharmacogenetic Analysis of BR

Pharmacogenetic Analysis of BR
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers

Similar presentations

Ads by Google